Mylan reported yet another quarter of declining sales, a trend the company has been seeing for the last couple of quarters. The sales decline was marred by increased competition and the continuing declining sales of the company’s allergy drug EpiPen, which in turn resulted in a 19% decline in sales in its North America sales. Revenue declined 1.2% to $2.68 billion from $2.71 billion a year ago. Mylan reported a profit increase of 31% for the quarter to $87.1 million or $0.17 per share, mainly influenced by an income tax benefit of $76.6 million. On an adjusted basis, the drug maker reported a 3.22% increase in its earnings per share to $0.96. https://news.alphastreet.com/mylan-1q-2018-results/
